Neratinib has been approved by the United States Food and Drug Administration for use in patients with adjuvant and metastatic HER2-positive (overexpressed/amplified) breast cancer based on the results of the ExteNET and NALA trials, respectively[19,20]. Here, ERBB2 is linked to breast carcinoma.